Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2024-07-04 Proxy Solicitation & In…
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
关于2024年第二次临时股东大会增加议案暨补充通知的公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement regarding the convening of the company's 2024 second extraordinary general meeting of shareholders, including the addition of a temporary proposal to the agenda. It includes information about the meeting date, voting procedures (both onsite and online), registration details, and attachments such as proxy forms and shareholder registration forms. The content focuses on procedural and administrative details related to the shareholder meeting rather than financial results, management changes, or regulatory filings. It is not a full annual or interim report, earnings release, or audit report. It is also not a declaration of voting results, but a notice about the meeting and its agenda. Therefore, this document fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2024-07-04 Chinese
关于回购公司股份比例达到1％暨回购进展的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. regarding the progress of its share repurchase program. It details the number of shares repurchased, the percentage of total shares repurchased (exceeding 1%), prices, amounts spent, and compliance with regulatory requirements. The document references previous announcements and regulatory guidelines related to share buybacks. It does not contain financial statements or detailed financial analysis but focuses on the status and compliance of the share repurchase activity. The document length is 2327 characters, which is relatively short and focused on a specific corporate action. Therefore, this document fits the category of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares.
2024-07-02 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the reduction of shares held by a significant shareholder (鼎泰海富投资管理有限公司) in the company 上海泓博智源医药股份有限公司. The content includes specifics about the shareholder's holdings before and after the reduction, the method of reduction (集中竞价 - centralized bidding), dates, and compliance with disclosure regulations. There is no indication of this being a full annual or interim financial report, audit report, or earnings release. It is a formal disclosure of a change in major shareholding, consistent with notifications required when a shareholder crosses thresholds (in this case, dropping below 5%). The document references relevant securities laws and regulatory requirements for such disclosures. Therefore, the document fits the category of Major Shareholding Notification (MRQ). The document length (5645 characters) and detailed content support it being the report itself, not just an announcement or certification.
2024-06-28 Chinese
关于持股5%以上股东减持至5%以下暨权益变动的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a formal announcement regarding a shareholder's reduction of holdings from above 5% to below 5% of the company's total shares. It includes details about the shareholder, the number of shares reduced, the percentage change, and compliance with relevant securities laws and regulations. The document references a "简式权益变动报告书" (Simplified Equity Change Report) and provides a detailed table of shareholding changes. There is no financial performance data, earnings information, or management discussion. The content fits the definition of a Major Shareholding Notification, which involves notifying changes in significant share ownership levels crossing thresholds (in this case, dropping below 5%). The document length is 2213 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2024-06-28 Chinese
第三届董事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 17th meeting of the third board of directors of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the approval of changes to the company's registered capital and amendments to the company bylaws, as well as the scheduling of a shareholders' meeting. The text includes voting results and procedural compliance statements. There are no financial statements, detailed financial performance data, or comprehensive management discussion and analysis. The document is primarily about board decisions and corporate governance matters related to capital changes and meeting arrangements. It is not a full annual or interim report, audit report, or earnings release. It is also not a simple announcement of a report publication but a substantive board resolution announcement. Therefore, the most appropriate classification is "Board/Management Information (MANG)" which covers announcements of changes or decisions by the board of directors.
2024-06-27 Chinese
关于召开2024年第二次临时股东大会通知公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2024 second extraordinary general meeting of shareholders for Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It includes information about the meeting time, location, voting procedures (both onsite and online), registration details, agenda items, and attachments such as proxy forms and registration forms. There is no financial data, earnings information, or audit content. The document is not a report itself but a formal announcement and invitation to shareholders to attend and vote at the meeting. It fits the definition of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2024-06-27 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.